한글목차

주요 7 시장(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)에서 Debio 1562에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동에 관한 인사이트 및 시장 예측 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 DLBCL에서 Debio 1562의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 신치료법)

제5장 Debio 1562시장 평가

• DLBCL에서 Debio 1562의 시장 전망
• 주요 7 시장 분석
  • 주요 7 시장의 DLBCL용 Debio 1562의 시장 규모
• 시장 분석 : 국가별
  • 미국의 DLBCL용 Debio 1562의 시장 규모
  • 독일의 DLBCL용 Debio 1562의 시장 규모
  • 영국의 DLBCL용 Debio 1562의 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

"Debio 1562 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about Debio 1562 for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets. A detailed picture of the Debio 1562 for DLBCL in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Debio 1562 for DLBCL. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Debio 1562 market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.

Drug Summary:

Debio 1562 (also called naratuximab emtansine) is an IV, an antibody-drug conjugate (ADC) that consists of a humanized IgG1 antibody K7153A that targets CD37, a cell surface antigens found on B-cell malignancies, that is covalently linked via the uncleavable, maleimide-derived thioether-based linker SMCC to the maytansinoid DM1, with potential pro-apoptotic and cytotoxic activities. The antibody moiety of Debio 1562 binds to CD37 on tumor B cells and induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), thereby showing pro-apoptotic activity. In addition, after the internalization of this agent and lysosomal degradation, the DM1 moiety binds to tubulin and inhibits tubulin polymerization and microtubule assembly, disrupting microtubule activity and cell division and eventually causing cell death in CD37-positive B cells.

The company anticipates the expected launch of Debio 1562 by 2025. Moreover, the patent protection of Debio 1562 till 2036, as per the company statement.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Debio 1562 description, mechanism of action, dosage and administration, research and development activities in Diffuse Large B-cell lymphoma (DLBCL).
• Elaborated details on Debio 1562 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Debio 1562 research and development activities in DLBCL across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Debio 1562.
• The report contains forecasted sales of Debio 1562 for DLBCL till 2032.
• Comprehensive coverage of the late-stage emerging therapies for DLBCL.
• The report also features the SWOT analysis with analyst views for Debio 1562 in DLBCL.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Debio 1562 Analytical Perspective by DelveInsight

In-depth Debio 1562 Market Assessment

This report provides a detailed market assessment of Debio 1562 for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

Debio 1562 Clinical Assessment

The report provides the clinical trials information of Debio 1562 for DLBCL covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Diffuse Large B-cell lymphoma (DLBCL) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Debio 1562 dominance.
• Other emerging products for DLBCL are expected to give tough market competition to Debio 1562 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Debio 1562 in DLBCL.
• Our in-depth analysis of the forecasted sales data of Debio 1562 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Debio 1562 in DLBCL.

Key Questions:

• What is the product type, route of administration and mechanism of action of Debio 1562?
• What is the clinical trial status of the study related to Debio 1562 in Diffuse Large B-cell lymphoma (DLBCL) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Debio 1562 development?
• What are the key designations that have been granted to Debio 1562 for DLBCL?
• What is the forecasted market scenario of Debio 1562 for DLBCL?
• What are the forecasted sales of Debio 1562 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to Debio 1562 for DLBCL?
• Which are the late-stage emerging therapies under development for the treatment of DLBCL?

Table of Contents

1. Report Introduction

2. Debio 1562 Overview in DLBCL

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Debio 1562 Market Assessment

• 5.1. Market Outlook of Debio 1562 in DLBCL
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Debio 1562 in the 7MM for DLBCL
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Debio 1562 in the United States for DLBCL
  • 5.3.2. Market Size of Debio 1562 in Germany for DLBCL
  • 5.3.3. Market Size of Debio 1562 in France for DLBCL
  • 5.3.4. Market Size of Debio 1562 in Italy for DLBCL
  • 5.3.5. Market Size of Debio 1562 in Spain for DLBCL
  • 5.3.6. Market Size of Debio 1562 in the United Kingdom for DLBCL
  • 5.3.7. Market Size of Debio 1562 in Japan for DLBCL

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options